Abstract |
We have been investigating the therapeutic efficacy of the thymidine analog 5-iodo-2'-deoxyuridine ( IUdR) when radiolabeled with the Auger electron emitter 125I in rats bearing intrathecal (i.t.) or intracerebral (i.c.) 9L gliosarcoma solid tumors. [125I] IUdR was infused i.t. (via subarachnoid catheters) or intracerebrally over a 5- or 2-day period; equimolar concentrations of [127I] IUdR were infused into control animals. Hind-leg paralysis and/or survival were followed over time. The results indicate that compared with [127I] IUdR, rats bearing intrathecal tumors and infused i.t. with [125I] IUdR showed significant prolongation of the onset of median paralysis (15.2 versus 9 days). Similarly, the median survival of rats bearing intracerebral tumors and infused i.c. with [125I] IUdR was significantly increased (24 versus 17 days). The data substantiate the antineoplastic potential of [125I] IUdR and indicate a promising role for this radiopharmaceutical in the treatment of CNS cancers.
|
Authors | A I Kassis, S J Adelstein |
Journal | Acta oncologica (Stockholm, Sweden)
(Acta Oncol)
Vol. 35
Issue 7
Pg. 935-9
( 1996)
ISSN: 0284-186X [Print] England |
PMID | 9004774
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Iodine Radioisotopes
- Idoxuridine
|
Topics |
- Animals
- Brain Neoplasms
(radiotherapy)
- Gliosarcoma
(radiotherapy)
- Idoxuridine
(pharmacokinetics, therapeutic use)
- Iodine Radioisotopes
(pharmacokinetics, therapeutic use)
- Male
- Neoplasm Transplantation
- Rats
- Rats, Inbred F344
- Tissue Distribution
|